Distinguished in Liver Cancer

Ana M. Matilla

Madrid, MD, ES 
Distinguished in Liver Cancer
Madrid, MD, ES 
OverviewLocationsClinical Research

Overview

Ana Matilla practices in Madrid, Spain. Ms. Matilla is rated as a Distinguished expert by MediFind in the treatment of Liver Cancer. Her top areas of expertise are Liver Cancer, Cirrhosis, Alcoholic Cirrhosis, Pseudomembranous Colitis, and Liver Transplant.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 20 articles and participated in 2 clinical trials in the study of Liver Cancer.

Gender
Female

Locations

Madrid, MD, Spain
Other Locations
Spain
Maranon, NC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II triAl of Cabozantinib for hepaTocellular carcInoma Patients intOlerant to Sorafenib Treatment or First Line Treatment Different to sorafeNib. (ACTION Trial)
A Phase II triAl of Cabozantinib for hepaTocellular carcInoma Patients intOlerant to Sorafenib Treatment or First Line Treatment Different to sorafeNib. (ACTION Trial)
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
The GOING Study: Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma Progressing Under Sorafenib or After Discontinuation of Atezolizumab Plus Bevacizumab
The GOING Study: Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma Progressing Under Sorafenib or After Discontinuation of Atezolizumab Plus Bevacizumab
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Regorafenib, Nivolumab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

27 Total Publications

Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy.
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: February 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Matilla's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile